





































Long-term safety and tolerability of cariprazine as adjunctive
therapy in major depressive disorder
Eduard Vietaa, Willie R. Earleyb, Maria V. Burgessb, Suresh Durgamb,
Changzheng Chenb, Yan Zhongb, Ágota Barabássyc and György Némethc
Lack of treatment response is a critical problem in major
depressive disorder (MDD). Cariprazine is a D3-preferring
dopamine D3/D2 receptor partial agonist and 5-HT1A partial
agonist. This phase 3, multicenter, open-label, long-term
(26-week), flexible-dose (1.5–4.5mg/day) study assessed the
long-term safety and tolerability of cariprazine used adjunctively
with antidepressant therapy in adult patients with MDDwho had
either completed a lead-in study (n=311) or had been newly
recruited (n=131). A higher percentage of continuing patients
(66.2%) than new patients (35.9%) completed the study. The
most common reason for discontinuation was adverse events
(AEs; 13.9%); 79% of patients experienced a treatment-
emergent AE [most common: akathisia (15.9%,) headache
(11.6%)]. Serious AEs occurred in 2% of patients; two deaths
occurred (one traffic accident, one completed suicide, both
considered unrelated to treatment). The mean changes in
clinical laboratory, cardiovascular, and ophthalmologic
parameters were generally not clinically relevant. Themean (SD)
changes from the open-label baseline in Montgomery–Åsberg
Depression Rating Scale total score and Clinical Global
Impression-Severity score at week 26 were −7.3 (9.5) and −1.0
(1.2), respectively. By week 26, 53.3% of patients were in
remission (Montgomery–Åsberg Depression Rating Scale total
score≤10). The results suggest that cariprazine was generally
safe and well tolerated as adjunctive therapy to treat MDD. Int
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Introduction
Major depressive disorder (MDD) is estimated to affect
∼ 15.4 million adults aged 18 years and older in the USA
each year (Greenberg et al., 2015), leading to significant
economic and societal burden (Ferrari et al., 2013). Although
pharmacological treatment is a mainstay for MDD, many
patients show an inadequate response to antidepressant
therapy (ADT). Roughly one-third of patients show remission
of depressive symptoms after the first treatment with ADT
(Trivedi et al., 2006), and patients who have successive treat-
ment failures may be less likely to respond to subsequent
treatment or more likely to relapse if they do respond (Rush
et al., 2006). Current treatments for patients who fail to
respond to ADT include switching to a different ADT (within
or between pharmacological classes), combination therapy,
adjunctive use of mood stabilizers or atypical antipsychotics,
and nonpharmacological treatments (American Psychiatric
Association, 2010; Davidson, 2010). Although atypical anti-
psychotics have shown efficacy as adjunctive therapy in var-
ious studies, their use may be limited by safety concerns,
including cardiovascular and metabolic side effects such as
weight gain, hyperglycemia, and dyslipidemia (Chen et al.,
2011; de Sousa et al., 2015).
Cariprazine is a dopamine D3/D2 receptor partial agonist that
is approved for the treatment of adults with schizophrenia
(USA and Europe) or manic or mixed episodes associated
with bipolar I disorder (USA); cariprazine is currently under
investigation for use as adjunctive treatment in MDD and
monotherapy in bipolar depression. Cariprazine binds with
higher affinity to D3 receptors than D2 receptors (Kiss et al.,
2010; Girgis et al., 2016), and recent preclinical and clinical
data suggest that enhanced D3 activity may play a role in
neuroadaptive changes related to antidepressant activity
(Leggio et al., 2013). Low affinity for serotonin 5-HT2C,
histamine H1, and adrenergic receptors may also contribute
to reduced potential for adverse effects associated typically
with antipsychotic treatment (Kiss et al., 2010). In addition,
cariprazine acts as a partial agonist at 5-HT1A receptors and
as an antagonist at 5-HT2B receptors (Kiss et al., 2010).
Antidepressant and anxiolytic effects may be mediated
through affinity for these receptors, which may enhance the
effects of selective serotonin reuptake inhibitors (Celada
et al., 2004). Previous long-term studies of cariprazine in
adult patients with schizophrenia or bipolar disorder have
shown few metabolic and cardiovascular side effects
(Durgam et al., 2016b; Cutler et al., 2018; Durgam et al., 2017;
Ketter et al., 2017; Nasrallah et al., 2017), which may make
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cariprazine an attractive option for patients who fail to
respond to ADT.
Cariprazine was safe and efficacious in an 8-week study
in adults with depressive episodes associated with bipolar
depression (Durgam et al., 2016c) and in a previous 8-week
study as an adjunctive treatment to ADT in adults with
MDD (Durgam et al., 2016a). In an additional 8-week study
of cariprazine as an adjunctive treatment to ADT in MDD
(NCT01715805) (Earley et al., 2018), cariprazine did not
differ from placebo on the primary efficacy measure, the
Montgomery–Åsberg Depression Rating Scale (MADRS)
(Montgomery and Asberg, 1979). To further evaluate the
safety of cariprazine plus adjunctive ADT in patients with
MDD, a long-term, open-label study (NCT01838876) was
also carried out. In this study, the negative 8-week study
(NCT01715805) served as a lead-in for some patients,
whereas other patients had been newly enrolled and had no
previous cariprazine exposure.
Patients and methods
The primary objective of this open-label study was to
assess the long-term safety and tolerability of cariprazine
1.5–4.5 mg/day as adjunctive therapy to ADT. The study
protocol was approved by an institutional review board at
each of 61 study centers; the study was carried out in
accordance with the Declaration of Helsinki, ICH
Guidance on General Considerations for Clinical Trials,
and ICH Good Clinical Practices. All patients provided
written, informed consent or other appropriate doc-
umentation according to local regulatory requirements.
Study design and participants
This phase 3, multicenter, flexible-dose, open-label study
included a 2-week screening period, where patients continued
their previously prescribed ADT, but did not receive car-
iprazine (i.e. cariprazine washout period for rollover patients),
a 26-week open-label cariprazine plus ADT period, and a
2-week safety follow-up period. Patients entering from the
8-week lead-in study (NCT01715805; rollover patients) con-
tinued ADT at their lead-in study dose; new patients con-
tinued their protocol-allowed ADT [citalopram, escitalopram,
fluoxetine, sertraline, paroxetine (CR), vilazodone, venlafaxine
(XR/IR/ER), desvenlafaxine, duloxetine, or bupropion (XL)].
On day 1, cariprazine was initiated at 0.5mg/day; the
dosage was increased by 0.5mg/day until the target dose of
3.0mg/day was received on days 6 and 7. Dosages could be
decreased to 1.5mg/day for tolerability reasons at any time
beginning at week 1 or increased to 4.5mg/day for inadequate
response between weeks 2 and 10.
The study included adult patients (18–65 years of age,
inclusive) who fulfilled Diagnostic and Statistical Manual of
Mental Disorders, 4th ed., text revision (DSM-IV-TR)
(American Psychiatric Association, 2000) criteria for MDD
on the basis of the Structured Clinical Interview, with a
current major depressive episode of at least 8 weeks’
duration and inadequate response (<50% improvement in
the current episode as established by the Antidepressant
Treatment Response Questionnaire) to ADT of adequate
dose and duration. Rollover patients who responded (as
determined by the clinical rating scale criteria) to placebo
plus ADT during a single-blind, open-label phase in the
lead-in study continued ADT plus single-blind placebo for
the duration of the lead-in study. Rollover patients who did
not respond during the single-blind open-label phase in the
lead-in study completed the 8-week randomized, double-
blind treatment phase (cariprazine or placebo plus con-
tinued ADT) before entering the screening period of the
current study with continued ADT. New patients were
included if they showed an ongoing inadequate response to
one or two protocol-allowed ADT trials of adequate dose
and duration. Patients were required to have normal find-
ings on physical examination, clinical laboratory test results,
and ECG results or abnormal findings that were judged not
to be clinically significant by the investigator.
Patients were excluded if they had a DSM-IV-TR axis I
diagnosis other than MDD within 6 months of the study or
an axis II disorder of sufficient severity to interfere with
participation. Lifetime history of certain psychiatric disorders
(e.g. schizophrenia, psychotic disorders, bipolar I/II disorder,
pervasive developmental disorder, cognitive disorders) was
exclusionary, as was alcohol or substance abuse/dependence
within 6 months of the study. Patients at significant risk of
suicide [investigator judgment, suicide attempt within the
last year, or MADRS Item 10 (suicidal thoughts) score≥5 at
visit 1 or 2] or injuring themselves or others (investigator
judgment) were excluded. Psychotropic medications were
not allowed, except for short-term use of zolpidem, zolpidem
extended release, zaleplon, eszopiclone, zopiclone, and chloral
hydrate for insomnia; benztropine, diphenhydramine, and
propranolol for extrapyramidal symptoms (EPS) or akathisia;
and lorazepam as a rescue medication.
Assessments
Safety assessments included adverse events [AEs, all visits
(screening, weeks 0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24,
26)], clinical laboratory parameters and ECGs (screening,
weeks 1, 8, 16, 26), vital signs (all visits), and ophthalmologic
examinations (screening, weeks 9 and 26). Suicidality as
measured by the Columbia-Suicide Severity Rating Scale (C-
SSRS) (Posner et al., 2011) was assessed at all visits. EPS were
assessed using the Barnes Akathisia Rating Scale (Barnes,
1989), the Simpson-Angus Scale (Simpson and Angus, 1970),
and the Abnormal Involuntary Movement Scale (Guy, 1976)
(screening, weeks 0, 4, 8, 12, 18, 26).
As the primary objective of this study was long-term safety
and tolerability, efficacy assessments were collected, but not
grouped into primary, secondary, or additional categories.
Assessments included change from baseline in the MADRS
total score and Clinical Global Impressions-Severity (CGI-S)
score. MADRS response (≥50% reduction from baseline
in MADRS total score) and remission (MADRS total
score≤10) rates were determined.
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Statistical analysis
Baseline for safety parameters for rollover patients who
completed the double-blind treatment was the lead-in
double-blind baseline; for new patients and rollover
patients who received continued open-label ADT, the
safety baseline was last nonmissing safety assessment before
the first dose of open-label cariprazine. Demographic and
baseline characteristics and safety parameters were sum-
marized using descriptive statistics for the safety population
(all patients who received at least one dose of cariprazine).
Demographic and other baseline characteristics were mea-
sured at lead-in study screening for rollover patients and at
open-label screening for new patients.
The efficacy baseline was the lead-in baseline for rollover
patients and the last available efficacy assessment before
the first dose of open-label cariprazine for new patients.
Efficacy parameters were summarized using descriptive
statistics for the intent-to-treat population (patients from
the safety population who had at least one efficacy
assessment after visit 2); no inferential statistical analyses
were carried out for efficacy parameters.
Results
Patient population
Of the 442 patients enrolled in the study, 345 fulfilled the
inclusion criteria, received the open-label study drug, and
were included in the safety population; 336 patients were
included in the intent-to-treat population. A total of 311
patients had continued from the lead-in study and 131
were new patients (Fig. 1). Of those continuing from the
lead-in study, 109 had received double-blind placebo
plus ADT, 108 had received double-blind cariprazine
plus ADT, and 94 had received single-blind placebo
plus ADT. Approximately 61% of the patients com-
pleted the study; a higher percentage of new patients
(64.1%) discontinued versus patients who completed
the lead-in study (double-blind treatment, 33.3%;
single-blind treatment, 34.9%). The most common
reasons for discontinuation overall were AEs (13.9%),
protocol violation (9.3%), and withdrawal of consent
(7.5%). A higher percentage of new patients (20.3%)
and patients who received placebo (13.8%) versus cariprazine
(9.8%) during the lead-in study discontinued because of
an AE. Akathisia (2.9%), restlessness (2.0%), anxiety (1.7%),
and fatigue (1.2%) were the most common AEs leading to
discontinuation.
Patient characteristics were generally similar between
groups (Table 1); however, new patients had a longer
duration of current depressive episode compared with
patients continuing from the lead-in study. In addition,
baseline MADRS scores were the lowest in patients who
received placebo plus ADT in the lead-in study, which
may be a result of this subgroup including patients who
responded to placebo plus ADT before randomization in
the lead-in study.
Extent of exposure
The mean (SD) duration of treatment was 134.7 (65.1)
days for cariprazine and 135.8 (64.1) days for ADT.
Approximately 50% of patients received the target car-
iprazine dose (3 mg/day) as their modal [i.e. most fre-
quently taken dose; 52.8% (182/345)] and final [50.4%
(174/345)] daily dose. The modal daily dose was 1.5 mg/
day for 99 (28.7%) patients and 4.5 mg/day for 59 (17.1%)
patients. Lorazepam was the most commonly used con-
comitant psychotropic medication (15.7% of patients
overall).
Adverse events and extrapyramidal symptoms
Approximately three-quarters of patients [79.4% (274/345)]
experienced a treatment-emergent adverse event (TEAE)
(Table 2). Most TEAEs (97.1%) were considered mild or
moderate; 64.1% of patients had TEAEs that were considered
to be related to treatment. TEAEs occurring in at least 10% of
patients overall were akathisia (15.9%) and headache (11.6%).
Serious adverse events (SAEs) occurred in 2.0% of patients
overall; no individual SAE occurred in more than one patient.
During the open-label treatment, two (0.6%) deaths occurred
[one road traffic accident (new patient); one completed suicide
(lead-in cariprazine 1.5–4.5mg/day)]. The patient who com-
pleted suicide had no reported depression-related TEAEs
and no history of C-SSRS-documented suicidal ideation or
behavior (lifetime history or during open-label treatment); no
information on the reason was available. Neither death was
considered by investigators to be related to treatment.
On the basis of EPS rating scales, treatment-emergent
akathisia (Barnes Akathisia Rating Scale baseline≤ 2 and
postbaseline> 2) and parkinsonism (Simpson–Angus
Scale baseline≤ 3 and postbaseline> 3) occurred in 18.5
and 1.8%, respectively, of patients overall (Table 3). Although
EPS-related TEAEs were reported in 98 (28.4%) patients,
only 17 (4.9%) discontinued because of EPS-related AEs.
Themajority of EPS-related TEAEs were consideredmild or
moderate in severity [96.9% (95/98)]. Approximately 21% of
patients used rescue medication, and anti-Parkinson medi-
cation was used by 4.9% of patients overall.
Suicidality
During the open-label treatment, three (0.9%) patients
experienced a TEAE of suicidal ideation (two patients
discontinued treatment; one event considered treatment-
related). Two patients experienced suicidality-related
SAEs [one patient (attempted suicide, discontinued)
and one patient died (death because of completed sui-
cide)]; neither event was considered to be treatment-
related.
C-SSRS-assessed suicidal ideation was reported by
37/345 (10.7%) patients during open-label treatment and
13/287 (4.5%) patients during safety follow-up. The
majority of reported suicidal ideations in the open-label
[27/37 (73.0%)] and safety follow-up [10/13 (76.9%)]
periods were in the least severe category (wish to be
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dead). In addition to the patient who completed suicide,
one patient who had received single-blind placebo in the
lead-in study had suicidal behavior (actual attempt),
which was considered moderate in intensity, not related
to treatment, and resulted in study discontinuation. The
patient had no C-SSRS lifetime history of suicidal ideation
Fig. 1
Patient disposition in the long-term safety and tolerability study of cariprazine as adjunctive therapy in major depressive disorder. aPatients who
responded to treatment during the prospective ADT period of the lead-in study and therefore remained on placebo plus ADT during the double-blind
treatment period of the lead-in study. bIncludes patients who completed the study and patients who discontinued participation in the study
prematurely. ADT, antidepressant therapy.











Age [mean (SD)] (years) 47.0 (10.3) 46.5 (10.7) 45.8 (11.1) 46.7 (10.5)
Male [n (%)] 50 (26.5) 28 (30.4) 18 (28.1) 96 (27.8)
Race [n (%)]
Caucasian 151 (79.9) 74 (80.4) 55 (85.9) 280 (81.2)
Black or African American 31 (16.4) 17 (18.5) 6 (9.4) 54 (15.7)
All other races 7 (3.7) 1 (1.1) 3 (4.7) 11 (3.2)
Weight [mean (SD)] (kg) 83.2 (18.7) 84.7 (18.8) 84.0 (18.1) 83.8 (18.6)
BMI [mean (SD)] (kg/m2) 29.7 (5.5) 30.0 (5.9) 29.8 (5.5) 29.8 (5.6)
Psychiatric history
Major depression [n (%)]
Recurrent 183 (96.8) 91 (98.9) 61 (95.3) 335 (97.1)
Single episode 6 (3.2) 1 (1.1) 3 (4.7) 10 (2.9)
Age at onset [mean (SD)] (years) 33.3 (12.5) 33.0 (12.2) 28.8 (11.9) 32.4 (12.4)
Duration of current episode [mean (SD)]
(weeks)
27.2 (11.5) 29.5 (11.7) 46.8 (45.8) 31.4 (23.4)
Baseline efficacy valuesa (ITT populationb) [mean (SD)]
MADRS total score 18.9 (9.1)c 25.8 (5.2) 30.9 (5.4) 22.8 (9.0)
CGI-S score 3.4 (1.1)c 4.2 (0.6) 4.2 (0.5) 3.8 (1.0)
ADT, antidepressant therapy; CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery–Åsberg Depression Rating Scale.
aFor patients from the lead-in study who were randomized to and completed double-blind treatment, the lead-in study efficacy baseline was used as the baseline for
this study.
bIntent-to-treat population (N=336).
cPatients who responded to treatment during the prospective ADT period of the lead-in study and were maintained on single-blind placebo and patients who were
inadequate responders who were randomized to placebo during the double-blind period.
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or behavior. The last dose of cariprazine was taken on day
132 and the suicidal behavior was recorded on day 134.
Clinical laboratory and safety parameters
The mean changes from baseline in clinical laboratory
parameters were generally small and not clinically relevant
(Table 4). Shifts from normal/borderline levels of total
(<240mg/dl) or low-density lipoprotein (<160mg/dl) cho-
lesterol at baseline to high levels (total: ≥240mg/dl; low-
density lipoprotein: ≥160mg/dl) at the end of the open-label
treatment occurred in 23/280 (8.2%) and 19/300 (6.3%)
patients, respectively. Shifts from normal high-density lipo-
protein cholesterol (≥40mg/dl) to low levels (<40mg/dl)
occurred in 19/313 (6.1%) patients. For fasting triglycerides,
shifts from normal/borderline (<200mg/dl) to high levels
(≥200mg/dl) occurred in 30/283 (10.6%) patients. Among
patients with normal fasting glucose (<100mg/dl) at baseline,
10/261 (3.8%) patients shifted to high levels (≥126mg/dl).
Less than one-third [98/341 (28.7%)] of patients developed an
increase in fasting glucose of at least 10mg/dl. Ophthalmologic
testing showed no evidence for retinal toxicity or lenticular
changes of clinical importance. Almost 20% of patients overall
experienced a 7% increase or more from baseline in body
weight during the open-label period; no remarkable pattern
was observed when stratified by the baseline BMI category.
The mean changes from baseline in cardiovascular safety
parameters were generally small and not clinically










Patients with any TEAE 149 (78.8) 75 (81.5) 50 (78.1) 274 (79.4)
Patients with SAEs 4 (2.1) 1 (1.1) 2 (3.1) 7 (2.0)
Patients with AEs leading to
discontinuation
26 (13.8) 9 (9.8) 13 (20.3) 48 (13.9)
AEs leading to discontinuations in at least 2% of patients in any group
Akathisia 8 (4.2) 1 (1.1) 1 (1.6) 10 (2.9)
Restlessness 4 (2.1) 3 (3.3) 0 7 (2.0)
Anxiety 2 (1.1) 2 (2.2) 2 (3.1) 6 (1.7)
Fatigue 1 (0.5) 1 (1.1) 2 (3.1) 4 (1.2)
Weight increased 0 0 2 (3.1) 2 (0.6)
Deaths 0 1 (1.1) 1 (1.6) 2 (0.6)
TEAEs in at least 5% of patients in any group, preferred term
Akathisia 29 (15.3) 14 (15.2) 12 (18.8) 55 (15.9)
Headache 26 (13.8) 11 (12.0) 3 (4.7) 40 (11.6)
Anxiety 20 (10.6) 7 (7.6) 7 (10.9) 34 (9.9)
Insomnia 19 (10.1) 7 (7.6) 8 (12.5) 34 (9.9)
Restlessness 18 (9.5) 7 (7.6) 9 (14.1) 34 (9.9)
Weight increased 22 (11.6) 4 (4.3) 8 (12.5) 34 (9.9)
Fatigue 17 (9.0) 10 (10.9) 3 (4.7) 30 (8.7)
Nasopharyngitis 13 (6.9) 12 (13.0) 5 (7.8) 30 (8.7)
Nausea 14 (7.4) 5 (5.4) 2 (3.1) 21 (6.1)
Dizziness 12 (6.3) 6 (6.5) 2 (3.1) 20 (5.8)
Sedation 15 (7.9) 2 (2.2) 2 (3.1) 19 (5.5)
Upper respiratory tract infection 8 (4.2) 5 (5.4) 2 (3.1) 15 (4.3)
For patients who did not participate in the safety follow-up period, AEs that occurred within 30 days after the last dose of open-label treatment were included.
ADT, antidepressant therapy; AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.










Patients with treatment-emergent EPS [n/N1 (%)]b
Akathisia (BARS baseline ≤2 and
postbaseline >2)
33/187 (17.6) 17/91 (18.7) 12/58 (20.7) 62/336 (18.5)
Parkinsonism (SAS baseline ≤3 and
postbaseline >3)
3/187 (1.6) 3/91 (3.3) 0 (0.0) 6/336 (1.8)
Patients with EPS-related TEAEs [n (%)]
At least one EPS-related TEAE 55 (29.1) 22 (23.9) 21 (32.8) 98 (28.4)
EPS-related TEAE (excluding akathisia/
restlessness)
16 (8.5) 4 (4.3) 3 (4.7) 23 (6.7)
Akathisia/restlessness 46 (24.3) 20 (21.7) 20 (31.3) 86 (24.9)
Patients with EPS-related AE resulting in
discontinuation
12 (6.3) 4 (4.3) 1 (1.6) 17 (4.9)
ADT, antidepressant therapy; AE, adverse event; BARS, Barnes Akathisia Rating Scale; EPS, extrapyramidal symptoms; SAS, Simpson–Angus Scale; TEAE, treatment-
emergent AE.
aFor patients who did not participate in the safety follow-up period, AEs that occurred within 30 days after the last dose of open-label treatment were included in the
summary.
bN1 is the number of patients who had a baseline and at least one postbaseline assessment; n is the subset of patients from N1 who fulfilled the criteria.
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relevant (Table 4). No patient had a QTcB or a QTcF
interval more than 500ms during open-label treatment.
Two patients each had a QTcB and QTcF interval increase
more than 60ms during the open-label treatment.
Efficacy assessments
Using an observed cases (OC) method (n=210), the mean
(SD) changes from open-label baseline to week 26 in the
MADRS total score and the CGI-S score were −7.3 (9.5)
and −1.0 (1.2), respectively; using a last observation carried
forward (LOCF) method (n=336), the mean (SD) changes
were −5.5 (10.3) and −0.7 (1.3), respectively. At week 26,
the rate of remission was 53.3% (112/210) on the basis of an
OC approach and 45.8% (154/336) on the basis of an LOCF
approach. At week 26 using an OC approach, 43.3%
(91/210) of patients were considered MADRS responders;
using an LOCF approach, 37.2% (125/336) of patients were
considered MADRS responders.
Discussion
In this phase 3, multicenter, open-label, long-term, flexible-
dose safety study in adult patients with a primary diagnosis
of MDD, cariprazine 1.5–4.5mg/day was generally safe and
well tolerated when used as long-term adjunctive therapy in
the treatment of MDD. Just under two-third of patients
completed the study, with 13.9% discontinuing because of
AEs. In general, the mean changes in laboratory values,
vital signs measurements, and ECG parameters were small
and not clinically relevant.
Although the percentage of patients discontinuing because
of AEs was comparable to the long-term studies of car-
iprazine monotherapy to treat schizophrenia (3–13%), the
overall percentage of patients who completed this study
(61%) was higher than what has been observed previously
with long-term cariprazine monotherapy (35–50%) (Durgam
et al., 2016b; Cutler et al., 2018; Durgam et al., 2017). Further,
the completion rate was only slightly lower than a previous
8-week study of adjunctive cariprazine for MDD (Durgam
et al., 2016a), which may be expected, given the increased
length of the present study. Discontinuations because of
AEs were lower in patients who had previously received
cariprazine compared with new patients and patients who
had received placebo during the lead-in study. As those who
Table 4 Change from baseline to the end of open-label treatment in clinical laboratory and cardiovascular parameters (safety population)
Parameters Lead-in placebo+ADT (n=189) Lead-in cariprazine +ADT (n=92) New patients (n=64) Total (N=345)
Metabolic parameters [mean change (SD)]
Total cholesterol (mg/dl) −2.7 (27.4) −4.8 (37.9) −7.4 (23.0) −4.1 (29.9)
Total LDL (mg/dl) −4.1 (25.0) −3.1 (31.4) −6.8 (20.4) −4.3 (26.1)
Total HDL (mg/dl) −1.5 (9.4) −2.4 (11.5) −3.8 (6.8) −2.1 (9.6)
Fasting triglycerides (mg/dl) 13.8 (48.9) 0.2 (55.9) 20.0 (61.4) 11.2 (53.6)
Fasting glucose (mg/dl) 4.9 (20.5) 4.3 (20.3) 3.4 (17.4) 4.4 (19.8)
Prolactin (ng/ml) 2.5 (8.7) 1.0 (5.7) 3.7 (5.4) 2.3 (7.5)
Body weight (kg) 1.6 (4.0) 1.7 (4.5) 1.3 (3.7) 1.6 (4.1)
Waist circumference (cm) 0.6 (6.4) 1.3 (5.7) 1.0 (4.4) 0.8 (5.9)
Change (≥7%) in body weight [n (%)]
≥7% increase from baseline 37 (19.6) 20 (21.7) 10 (15.6) 67 (19.4)
≥7% increase by baseline BMI categories (kg/m2) [n/N1 (%)]a
<18.5 0/0 0/1 0/1 0/2
≥18.5 and <25 14/46 (30.4) 6/27 (22.2) 2/13 (15.4) 22/86 (25.6)
≥25 and <30 9/52 (17.3) 9/23 (39.1) 1/18 (5.6) 19/93 (20.4)
≥30 14/91 (15.4) 5/41 (12.2) 7/32 (21.9) 26/164 (15.9)
≥7% decrease from baseline 10 (5.3) 6 (6.5) 2 (3.1) 18 (5.2)
Clinical laboratory parameters [mean change (SD)]
CPK (U/l) 177.1 (2566.5) −4.1 (149.8) −65.8 (565.1) 83.4 (1914.9)
ALT (U/l) 1.1 (18.3) 1.5 (16.4) 24.3 (198.0) 5.5 (86.8)
AST (U/l) 2.1 (39.1) −1.1 (9.9) 6.2 (67.3) 2.0 (41.2)
Total bilirubin (mg/dl) 0.0 (0.2) 0.0 (0.2) 0.0 (0.3) 0.0 (0.2)
Alkaline phosphatase (U/l) 0.6 (10.1) 1.1 (10.9) 0.6 (12.4) 0.7 (10.7)
Blood pressure and pulse [mean change (SD)]
Systolic blood pressure (mmHg) 0.3 (10.6) −1.5 (12.9) −2.2 (12.1) −0.7 (11.5)
Diastolic blood pressure (mmHg) 0.4 (7.5) −0.4 (7.6) 0.1 (6.8) 0.1 (7.4)
Pulse (beats/min) 1.1 (10.5) 0.9 (10.5) 0.6 (11.8) 1.0 (10.7)
Orthostatic hypotension [n (%)]b 38 (20.1) 21 (22.8) 16 (25.0) 75 (21.7)
ECG [mean change (SD)]
Ventricular heart rate (beats/min) 2.4 (9.7) 2.3 (10.1) 6.0 (10.3) 3.0 (10.0)
PR interval (ms) −1.0 (12.3) −0.3 (12.0) 0.5 (12.5) −0.5 (12.3)
QRS interval (ms) −0.5 (8.0) −0.7 (7.8) −0.8 (7.1) −0.6 (7.8)
QT interval (ms) −7.9 (25.3) −5.3 (25.5) −13.4 (22.9) −8.2 (25.0)
QTcB interval (ms) −1.4 (19.4) 1.6 (18.0) 4.0 (19.1) 0.4 (19.0)
QTcF interval (ms) −3.7 (17.2) −0.8 (15.5) −2.0 (14.6) −2.6 (16.3)
ADT, antidepressant therapy; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
aN1 is the number of patients with baseline BMI in the given category and ≥1 postbaseline weight measurement during open-label treatment; n is the subset of patients in
N1 who fulfilled the criteria at least once during the open-label treatment period.
bOrthostatic hypotension was defined as a reduction of ≥20 mmHg in systolic blood pressure or a reduction of ≥10mmHg in diastolic blood pressure while changing
from the supine to the standing position.
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had received cariprazine for the longest duration discontinued
at a lower rate, this may suggest that some patients are able to
acclimate to AEs that they initially consider troublesome or
that some AEs may reduce over time.
The most common AE in all subgroups was akathisia,
which is consistent with previous long-term cariprazine
studies in patients with schizophrenia (Durgam et al.,
2016b; Cutler et al., 2018; Durgam et al., 2017) as well as a
previous short-term study of cariprazine as adjunctive
therapy to ADT in MDD (Durgam et al., 2016a). The
incidence of SAEs was low, with only 2.0% patients
experiencing at least one SAE. Two patients died during
the study; both deaths were determined by the investi-
gator to be unrelated to treatment. In addition, EPS are
commonly experienced with atypical antipsychotics.
Although just over one-quarter of patients experienced at
least one EPS-related TEAE (including akathisia/restlessness)
in this study, relatively few patients discontinued as a result,
suggesting that EPS were manageable for many patients.
Rollover patients who had received cariprazine experienced
fewer EPS-related TEAEs, suggesting that events may occur
early in treatment and decrease over time. This finding is in
line with previous results for cariprazine monotherapy in
schizophrenia (Earley et al., 2017b) and bipolar mania (Earley
et al., 2017a), which showed that akathisia typically occurred
within the first few weeks of treatment and resolved quickly
(within ~2 weeks).
Patients with MDD commonly show suicidal ideations and
behavior (Isometsa, 2014). Studies have found that the
absolute lifetime risk of suicide in patients with MDD is
between 4 and 7%, and illness-related factors, such as severe
or recurrent depression or failure to achieve remission,
further exacerbate risk (Isometsa, 2014). History of suicide
attempt is 30–40% of all patients with MDD, and having a
current depressive episode represents a high-risk state for
suicidal ideation and behavior (Isometsa, 2014). As this
study required patients to have a current episode of at least
8 weeks, these patients already represent a higher-risk
category for suicidal behavior even though risk of suicide
was an exclusion criterion. Adjunctive treatment with car-
iprazine did not appear to increase the risk of suicidal
behavior or ideation, nor were any clear trends in suicidality
noted among patients who had or had not previously been
exposed to cariprazine. In addition to one patient who
completed suicide, which was considered unrelated to
treatment, there was only one report of suicidal behavior and
the incidence of suicidal ideation was 11%.
Metabolic side effects may limit the use of atypical
antipsychotics in the treatment of MDD. It is noteworthy
that weight gain is common with some atypical antipsychotics
used as monotherapy (e.g. quetiapine) or adjunctive therapy
(e.g. olanzapine/fluoxetine combination) for MDD (Chen
et al., 2011). The mean weight gain with cariprazine in this
trial (+1.6 kg) was similar to previously reported trials with
risperidone and aripiprazole (+2.0 kg, each) (Chen et al., 2011),
suggesting weight gain that was comparable to atypical anti-
psychotics that are on the lower end of the weight gain
spectrum. The mean weight gain in this study was higher
than that in short-term bipolar mania and schizophrenia
studies using monotherapy cariprazine (Earley et al., 2017a,
2017b); however, polypharmacy with adjunctive cariprazine
may act to compound the weight gain typically observed with
ADTs (Fava, 2000). Weight increase of at least 7% were
observed in just under 20% of patients, which was less
than that in previous long-term studies with cariprazine
monotherapy (range: 26–33%) (Durgam et al., 2016b, 2017;
Cutler et al., 2018; Nasrallah et al., 2017). In this study, changes
in cardiovascular and hematology parameters were generally
small, and none were considered clinically relevant. Further,
no clear trends were noted among patients who had
previously received cariprazine and patients who were new to
cariprazine treatment.
In terms of efficacy assessments, the open-label trial
design is a limitation, but may provide some descriptive
measures of drug effectiveness (Vieta et al., 2017).
MADRS and CGI-S scores decreased during open-label
treatment, suggesting that long-term treatment was not
associated with worsening of MADRS scores. Furthermore,
using an OC approach, almost half of the patients respon-
ded to treatment and over half of the patients achieved
remission. This is an interesting finding as inclusion criteria
required patients to have inadequate response to previous
treatments. However, it is not possible to draw efficacy
conclusions as this was an open-label study and it was not
designed to assess efficacy.
The limitations of the study include the open-label study
design, and the absence of a placebo-comparator or an
active-comparator group. Although the flexible-dose
regimen more closely mimics real-world clinical practice,
it limits the ability to draw conclusions on dose–response
relationships for safety parameters. The inclusion of both
rollover and new patients further limits interpretation of
the data and may have biased safety outcomes. Namely,
the subset of patients with previous exposure to car-
iprazine might be considered an enriched sample with a
higher probability to remain well in comparison with
newly enrolled patients. Further, new patients had higher
baseline symptom severity than rollover patients, which
allowed for greater decreases in rating scale scores during
open-label treatment for these patients than for patients
who had been treated with cariprazine in the lead-in study.
In addition, since cariprazine was being used as adjunctive
therapy, it is difficult to make direct safety comparisons
between this trial and previously published trials with
cariprazine monotherapy. Although the wide range of
allowed ADTs presents a realistic scenario of real-world
clinical practice, it is likely that some AEs, such as weight
gain, or other safety parameters might have been related to
a specific ADT and not cariprazine; without a placebo
group, it is not possible to fully assess this likelihood.
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Conclusion
In patients with MDD, cariprazine was generally safe and
well tolerated when used as adjunctive treatment to
ADT. The safety profile was generally consistent with
that observed in patients with MDD after short-term use
in the previous adjunctive cariprazine study and was
consistent with the known pharmacological properties of
cariprazine. No unexpected AEs emerged that appear to
be related to long-term exposure or combined treatment
with ADT, and no clinically relevant changes in the
majority of safety parameters were observed.
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